Trinity Biotech Plc ADR (NASDAQ: TRIB)’s stock price has increased by 0.32 compared to its previous closing price of 0.90. However, the company has seen a 6.28% increase in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-24 that DUBLIN, Dec. 24, 2024 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has entered into amended agreements with its primary lender, Perceptive Advisors. These strategic amendments provide additional liquidity, further enhancing the Company’s near-term financial position as it advances its Comprehensive Transformation Plan and continues development of its innovative continuous glucose monitoring (CGM) technology.
Is It Worth Investing in Trinity Biotech Plc ADR (NASDAQ: TRIB) Right Now?
TRIB has 36-month beta value of 0.99. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TRIB is 10.96M, and currently, short sellers hold a 0.64% ratio of that float. The average trading volume of TRIB on December 24, 2024 was 165.98K shares.
TRIB’s Market Performance
TRIB stock saw a decrease of 6.28% in the past week, with a monthly decline of -26.24% and a quarterly a decrease of -24.38%. The volatility ratio for the week is 15.10%, and the volatility levels for the last 30 days are 12.22% for Trinity Biotech Plc ADR (TRIB). The simple moving average for the last 20 days is -4.28% for TRIB stock, with a simple moving average of -52.20% for the last 200 days.
Analysts’ Opinion of TRIB
ROTH Capital gave a rating of “Buy” to TRIB, setting the target price at $20 in the report published on July 29th of the previous year.
TRIB Trading at -33.19% from the 50-Day Moving Average
After a stumble in the market that brought TRIB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.65% of loss for the given period.
Volatility was left at 12.22%, however, over the last 30 days, the volatility rate increased by 15.10%, as shares sank -23.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -50.00% lower at present.
During the last 5 trading sessions, TRIB rose by +1.57%, which changed the moving average for the period of 200-days by -61.43% in comparison to the 20-day moving average, which settled at $0.9382. In addition, Trinity Biotech Plc ADR saw -58.05% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for TRIB
Current profitability levels for the company are sitting at:
- -0.22 for the present operating margin
- 0.34 for the gross margin
The net margin for Trinity Biotech Plc ADR stands at -0.34. The total capital return value is set at -0.19.
Based on Trinity Biotech Plc ADR (TRIB), the company’s capital structure generated 1.47 points at debt to capital in total, while cash flow to debt ratio is standing at -0.15. The debt to equity ratio resting at -3.11. The interest coverage ratio of the stock is -1.66.
Currently, EBITDA for the company is -24.1 million with net debt to EBITDA at -9.07. When we switch over and look at the enterprise to sales, we see a ratio of 1.76. The receivables turnover for the company is 2.76for trailing twelve months and the total asset turnover is 0.61. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.64.
Conclusion
To put it simply, Trinity Biotech Plc ADR (TRIB) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
